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Introduction
Acyclovir is very effective in inhibiting the replica-
tion of herpes simplex virus (HSV). Although acyclovir
is the standard antiviral drug used to treat most
herpesvirus infections, its poor oral bioavailability
(15%-20% of the administered dose) has led to the
development of newer nucleoside analogues and pro-
drugs that have a better oral bioavailibity. Valaciclovir
hydrochloride (Valtrex; GlaxoWellcome, Manchester,
United Kingdom) is the l-valyl ester of acyclovir
and is well absorbed when given orally. It is rapidly
converted to acyclovir by hepatic metabolism, which
results in more than 50% of the drug’s bioavailability:
a three- to five-fold increase when compared with the
oral administration of acyclovir. When valaciclovir is
given orally at a dosage of 1000 mg three times a day
to healthy adult volunteers, the plasma acyclovir levels
are comparable to those achieved by the intravenous
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infusion of acyclovir at 5 mg/kg body weight.1 This
prodrug of acyclovir may thus provide a more con-
venient oral regimen to treat HSV infections and would
be particularly useful when a high level of plasma acy-
clovir is required. Clinical experience with valaciclovir
is currently limited to the treatment of herpes genitalis
and herpes zoster in immunocompetent adults.2,3 How-
ever, valaciclovir may also be useful as continuation
therapy after initial intravenous acyclovir treatment for
more serious infections. In this paper, we present the
first report of using valaciclovir in a child with herpes
simplex encephalitis (HSE).
Case report
A 12-year-old Chinese boy was admitted to the Yan
Chai Hospital in March 1997 for a history of left-hand
weakness, slurring of speech and dripping of saliva
from the left angle of the mouth that had lasted 1 day,
and generalised convulsions. He had no recent history
of head injury or change in behaviour. Physical ex-
amination showed the patient to have claw-hand of
the left hand, which had a motor power of grade 2.
The proximal part of left upper limb, right upper limb,
and both lower limbs were normal. The left facial
muscles showed weakness, whereas other cranial
nerves were normal. The body temperature was 36°C,
peripheral white blood cell count was 14.2 x 109 /L and
erythrocyte sedimentation rate was 47 mm/h (normal
range, 0-20 mm/h). Computed tomography showed an
ill-defined hypodense lesion over the right temporal
lobe. Electroencephalography revealed intermittent
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runs of irregular slow-wave activity over the right
central region; activity was enhanced during hyper-
ventilation. The cerebrospinal fluid (CSF) that was
taken on the day of admission showed pleocytosis—
that is, a white blood cell count of 9x106 /L, and a red
blood cell count of 22x106 /L. Protein and glucose con-
centrations were within the normal range; oligoclonal
proteins were found in the CSF. Microbiological
investigations of the CSF included virus isolation
and the complement fixation test to detect anti-HSV
antibodies, and gave negative results.
Empirical treatment with intravenous acyclovir
10 mg/kg every 8 hours, phenytoin, and cefotaxime
was started on the day of hospital admission, while
awaiting results of further investigations. On the day
of admission, the patient experienced two episodes
of generalised tonic-clonic convulsion and loss of
consciousness lasting approximately 1 minute each,
as well as frequent attacks of focal convulsion of the
left upper limb that lasted approximately 1 minute
each. Weakness of left facial and hand muscles sub-
sided completely on day 4, and no more convulsions
occurred. Polymerase chain reaction (PCR) analysis 4
of the CSF specimen confirmed the diagnosis of
HSE on day 7. The dosage of acyclovir was increased
and was intended as 3-week maintenance therapy in
accordance with recently published guidelines.5 How-
ever, the patient developed a significant local skin
reaction—namely, erythema, tenderness, and blister-
ing over the infusion sites—on day 2, which became
progressively worse despite the slow infusion of
acyclovir with normal saline and the frequent change
of infusion site. In view of the clinical improvement
and the severe skin reaction after 11 days of intra-
venous acyclovir, antiviral therapy was changed to oral
valaciclovir 1000 mg three times a day. After 2 days
of valaciclovir treatment, the patient was discharged
home and completed the remaining 8 days of the oral
valaciclovir regimen at home. The 10-day course of
oral valaciclovir was well tolerated and no new skin
lesions developed. There was no clinical relapse of
encephalitis, and no residual neurological deficits were
detected on follow-up visits at 1 week and 1 month
after discharge.
Discussion
To confirm a diagnosis of HSE is a difficult challenge.
The disease, particularly in its early stages, can mimic
a variety of other neurological illnesses. The diagno-
sis requires a concerted clinical and laboratory team
effort, but definitive aetiological diagnosis remains the
task of the virus laboratory. The European Union’s
Concerted Action on Virus Meningitis and Encephali-
tis has produced a comprehensive review of various
means of confirming the diagnosis of HSE.5 Imaging
and electroencephalography are neither sensitive
nor specific, particularly in the diagnosis of HSE in its
early stages. In contrast, biopsy examination of the
brain is both sensitive and specific, and a reliable
diagnosis can often be obtained 4 to 5 days after the
onset of illness. The invasive nature of performing a
brain biopsy, however, limits its application. The
detection of intrathecal HSV-specific antibodies has
been a valuable diagnostic test, but 10 to 12 days are
usually needed to produce a detectable amount of
antibody. As a result, the diagnosis is mainly retro-
spective and carries little influence on the management
of individual cases.
The sensitivity of the detection of HSV in CSF by
either isolation or antigen detection is far below the
satisfactory level.5 Fortunately, nested PCR provides
a rapid, sensitive, specific, and less invasive method
to detect HSV DNA in a sample of CSF. Although
nested PCR is more susceptible to producing artefacts
due to contamination than are traditional methods such
as virus isolation or serology, diagnostic PCR has been
successfully used by many clinical microbiology
laboratories and is likely to be the gold standard for
the diagnosis of HSE.6 In this case, the positive PCR
result was the only unequivocal finding, not only to
confirm the diagnosis, but also to support the continu-
ation of antiviral therapy when complications occurred.
Molecular diagnosis of HSE, such as PCR analysis,
is still not widely available in Hong Kong, and its
development for use in routine clinical service should
be encouraged.
The availability of PCR analysis as a routine diag-
nostic method has also redefined the spectrum of
HSV infections of the central nervous system. The
method has shown that some patients with HSE re-
lapse within 2 to 3 weeks of an apparent recovery,7
and in a series described by Kimura et al,8 four of 15
children with HSE had a clinical relapse. The patho-
genesis of clinical relapse of HSE is still controver-
sial; possible causes are persistent infection, the
reactivation of latent virus, or postinfectious enceph-
alitis.9 In the study by Kimura et al,8 HSV DNA was
detected in samples of CSF that were taken during
relapse following a standard course of acyclovir
treatment, thus indicating that the then recommended
therapy of acyclovir 10 mg/kg every 8 hours for
10 to 14 days was insufficient. A longer duration of
antiviral therapy has recently been recommended to
prevent relapse.5
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Although major side effects of acyclovir are un-
common, skin reactions (as observed in this case) have
been reported.10 In this case, intravenous infusion of
acyclovir was changed to oral valaciclovir, which also
allowed an earlier discharge from hospital. Owing
to the lack of a readily available assay, the plasma
levels of acyclovir following the intravenous infusion
of acyclovir and oral administration of valaciclovir
were not measured. Based on published data,1 the
dosage of oral valaciclovir that was used for this
patient was expected to achieve a plasma acyclovir
level equivalent to that due to intravenous infusion
of acyclovir at a dosage of 5 mg/kg every 8 hours.
With the increasing use of a higher dose and longer
duration of intravenous acyclovir for HSE in particu-
lar, clinicians may encounter more cases of minor
side effects, and more patients will have to remain
hospitalised for intravenous therapy despite recovery
from the acute illness. Hence, an alternative mode
of continuation therapy may be required in certain
circumstances, and oral valaciclovir therapy could be
an option, especially because of the added benefit of
allowing earlier discharge home if this is indicated.
In the treatment of infections of the central nervous
system, drug bioavailability across the blood-brain
barrier is more important than drug bioavailability
in the plasma. Because valaciclovir (a prodrug of
acyclovir) is rapidly converted to acyclovir by hepatic
metabolism, the CSF penetration of valaciclovir should
be equivalent to that of intravenous acyclovir (ie the
concentration in the CSF is approximately 50% of
that in the plasma).
In this case, the patient’s condition improved by
day 4 of hospital admission. This time course could
represent the natural course of a mild case of HSE, or
it could indicate a response to the initial acyclovir
therapy. Although the efficacy of oral valaciclovir
cannot be concluded from a single case report, the
use of oral valaciclovir as continuation therapy and
the subsequent complete recovery without clinical
relapse and allergic reaction have been illustrated. It
may be worthwhile to perform a controlled clinical
trial to evaluate the efficacy of valaciclovir and other
newer drugs in the treatment of HSE.
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